NASDAQ:MIRM Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis $100.61 +2.31 (+2.35%) Closing price 09/10/2026 04:00 PM EasternExtended Trading$101.84 +1.22 (+1.22%) As of 07:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Mirum Pharmaceuticals Stock (NASDAQ:MIRM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mirum Pharmaceuticals alerts:Sign Up Key Stats Today's Range$97.48▼$101.1850-Day Range$94.11▼$128.5752-Week Range$63.23▼$130.00Volume586,934 shsAverage Volume466,135 shsMarket Capitalization$6.53 billionP/E RatioN/ADividend YieldN/APrice Target$137.31Consensus RatingModerate Buy Company Overview Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with an emphasis on liver and gastrointestinal disorders. The company’s medicines are intended to address serious conditions for which available treatment options are limited. Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor approved in the United States for the treatment of cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible patients. The company is also commercializing CHOLBAM (cholic acid) and CHENODAL (chenodiol), bile acid therapies used for certain rare metabolic and liver disorders. Founded in 2018 and headquartered in Foster City, California, Mirum has expanded its operations internationally as it seeks regulatory approvals and commercial opportunities in additional markets. Its development pipeline includes investigational therapies for other cholestatic liver diseases, including conditions such as primary sclerosing cholangitis and primary biliary cholangitis. Mirum is led by President and Chief Executive Officer Christopher Peetz.AI Generated. May Contain Errors. Read More Mirum Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreMIRM MarketRank™: Mirum Pharmaceuticals scored higher than 59% of companies evaluated by MarketBeat, and ranked 243rd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingMirum Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 1 strong buy rating, 13 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMirum Pharmaceuticals has a consensus price target of $137.31, representing about 36.5% upside from its current price of $100.61.Amount of Analyst CoverageMirum Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Mirum Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($1.31) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirum Pharmaceuticals is -6.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirum Pharmaceuticals is -6.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMirum Pharmaceuticals has a P/B Ratio of 16.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mirum Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.37% of the float of Mirum Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMirum Pharmaceuticals has a short interest ratio ("days to cover") of 13.21, which indicates bearish sentiment.Change versus previous monthShort interest in Mirum Pharmaceuticals has recently decreased by 4.89%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMirum Pharmaceuticals does not currently pay a dividend.Dividend GrowthMirum Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.52 News SentimentMirum Pharmaceuticals has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Mirum Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 3 people have searched for MIRM on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows4 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Mirum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,445,462.00 in company stock.Percentage Held by Insiders8.32% of the stock of Mirum Pharmaceuticals is held by insiders.Percentage Held by InstitutionsMirum Pharmaceuticals has minimal institutional ownership at this time.Read more about Mirum Pharmaceuticals' insider trading history. Receive MIRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MIRM Stock News HeadlinesMirum Pharmaceuticals, Inc. (MIRM) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 10 at 6:10 PM | seekingalpha.comMirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical OfficerSeptember 8 at 9:00 AM | businesswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.September 11 at 1:00 AM | Profits Run (Ad)Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 6, 2026 | americanbankingnews.comMirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 658 SharesSeptember 4, 2026 | insidertrades.comMirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 40,000 SharesAugust 20, 2026 | insidertrades.comInsider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells $599,499.90 in StockAugust 13, 2026 | insidertrades.comChristopher Peetz Sells 20,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) StockAugust 12, 2026 | insidertrades.comSee More Headlines MIRM Stock Analysis - Frequently Asked Questions How have MIRM shares performed this year? Mirum Pharmaceuticals' stock was trading at $78.99 at the beginning of 2026. Since then, MIRM shares have increased by 27.4% and is now trading at $100.61. How were Mirum Pharmaceuticals' earnings last quarter? Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) issued its quarterly earnings results on Wednesday, August, 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.74) by $0.32. The business's revenue was up 37.9% compared to the same quarter last year. Read the conference call transcript. When did Mirum Pharmaceuticals IPO? Mirum Pharmaceuticals (MIRM) raised $75 million in an initial public offering on Thursday, July 18th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers. Who are Mirum Pharmaceuticals' major shareholders? Top institutional shareholders of Mirum Pharmaceuticals include Jupiter Topco LLC (9.10%), California State Teachers Retirement System (8.66%), BlackRock Inc. (7.20%) and William Blair Investment Management LLC (2.16%). Insiders that own company stock include Patrick J Heron, Christopher Peetz, Lara Longpre, Peter Radovich, Eric Bjerkholt, Pamela Vig, Joanne Quan, Laura Brege, Jolanda Howe, Saira Ramasastry and Michael G Grey. View institutional ownership trends. How do I buy shares of Mirum Pharmaceuticals? Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mirum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mirum Pharmaceuticals investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings8/05/2026Today9/11/2026H.C. Wainwright 28th Annual Global Investment Conference9/15/2026Morgan Stanley 24th Annual Global Healthcare Conference9/16/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 MIRM's financial health is in the Yellow zone, according to TradeSmith. MIRM has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MIRM CIK1759425 Webmirumpharma.com Phone(650) 667-4085FaxN/AEmployees433Year Founded2018Price Target and Rating Average Price Target for Mirum Pharmaceuticals$137.31 High Price Target$165.00 Low Price Target$118.00 Potential Upside/Downside+36.5%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($14.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.36 million Net Margins-139.18% Pretax Margin-138.74% Return on Equity-36.28% Return on Assets-8.54% Debt Debt-to-Equity Ratio1.28 Current Ratio2.86 Quick Ratio2.74 Sales & Book Value Annual Sales$521.31 million Price / Sales12.53 Cash Flow$0.05 per share Price / Cash Flow1,928.24 Book Value$6.12 per share Price / Book16.44Miscellaneous Outstanding Shares64,930,000Free Float59,530,000Market Cap$6.53 billion OptionableOptionable Beta0.49 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:MIRM) was last updated on 9/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
